Tiziana Life Sciences #TILS Appoints Gregor MacRae to strengthen the Board January 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 21 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, is pleased to announce appointment of Mr. Gregor MacRae to its Board as a Non-executive Director. Mr. Gregor MacRae holds a Law degree (LLB Hons) from the University of Birmingham. He is a qualified Chartered Accountant (ICAEW) and has been a financial and business strategy…

Tiziana Life Sciences #TILS – Exec Chairman Gabriele Cerrone purchases more shares January 14, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 14 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on the 13 January 2020 it was informed that on that date, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought 28,500 Ordinary Shares at a price of 43 pence per Ordinary Share, as set out below. The…

Tiziana Life Science (Nasdaq: TLSA / AIM: TILS) – Proposed Cancellation from AIM January 13, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 13 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has appointed advisers in relation to an intended redomicile of the Company to Bermuda which is anticipated to occur by Q2-2020, as a consequence of the redomicile the Company will not be seeking to re-admit its ordinary shares on AIM and will therefore seek shareholder consent for its shares to be cancelled from AIM when the…

Tiziana Life Sciences #TILS – Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab is Well-tolerated in Healthy Volunteers January 9, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 9 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to report completion of a Phase 1 clinical study of Foralumab, a fully human anti-CD3 monoclonal antibody (“mAb”), in healthy subjects. The proprietary oral formulation, comprising the lyophilized and stabilized free-flowing powder of formulated Foralumab encapsulated in an enteric-coated capsule, was well-tolerated at all doses tested and there were no drug-related…

Tiziana Life Sciences #TILS – Director Dealing, Exec Chairman Gabriele Cerrone purchases 12,500 ADSs January 2, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 2 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 31 December 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought 12,500 ADSs each representing 5 ordinary shares of nominal value 3p each in the capital of the Company at a price of US$2.79 per ADS,…

Tiziana Life Sciences #TILS – Initiates Phase 1 Clinical Trial with Orally Administered Foralumab, a Fully Human anti-CD3 monoclonal antibody, in Healthy Volunteers December 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

London/New York, 4 December 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a clinical-stage biotechnology company focused on developing innovative therapeutics for inflammatory diseases and cancers, is pleased to announce initiation of a Phase I clinical trial in healthy volunteers with a proprietary oral formulation of Foralumab encapsulated in enteric-coated capsules. The primary objective of this single ascending dose (SAD) phase 1 study, being led by Dr. Tanuja Chitnis at the Brigham and Women’s Hospital,…

Alan Green talks Santa Rally, Funds, JD Sports #JD, Tiziana Life Sciences #TILS & Itaconix #ITX on Vox Markets podcast December 3, 2019 – Posted in: Blog, Tiziana Life Sciences (TILS)

Alan Green discusses Santa Rally, funds, JD Sports #JD, Tiziana Life Sciences #TILS & Itaconix #ITX with Justin Waite on the Vox Markets podcast. The interview is 19 minutes 13 seconds in.

Tiziana Life Sci (TILS) Issue of Equity and Directorate Change November 20, 2019 – Posted in: Tiziana Life Sciences (TILS)

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 20 November 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has issued 190,698 ordinary shares of 3p each (“Ordinary Shares”) credited as fully paid at a price of 43p per share in satisfaction of a…

Tiziana Life Sciences #TILS – Issue of convertible unsecured loan notes with warrants to raise £1,434,000 November 1, 2019 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 1 November 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has raised £1,434,000 of finance by way of the issue of convertible unsecured loan notes (the “Loan Notes”), with warrants attached, for working capital purposes. The Company previously announced its intention to raise additional equity share capital by way of an…

Tiziana Life Sciences #TILS – Change to ADS ratio October 30, 2019 – Posted in: Tiziana Life Sciences (TILS)

London, 30 October 2019 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level I American Depositary Receipt (“ADR”) programme. The former ratio of ten (10) ordinary shares to one (1) American Depositary Share (“ADS”) has been changed to five (5) ordinary shares per one (1) ADS effective on 29 October 2019. There will be no change to the underlying ordinary shares. ADR record date: 21 October 2019…

« First
Previous
1
...
3
4
5
6
7
Next
Last »